19 Multiple Myeloma Clinical Trials in Duarte, CA (2026)

Q: How do I join a clinical trial in Duarte?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Duarte research site will contact you.

Recruiting Multiple Myeloma Studies in Duarte

NCT05552222Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) ...

Duarte, CAPHASE31,590 participantsJanssen Research & Development, LLC

View Study Details

NCT07225738Recruiting

A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients

This study assesses the impact of cannabis (also commonly called marijuana, weed, or THC) use on quality of life among patients with multiple myeloma who are receiving chemotherapy. It also evaluates ...

Duarte, CA700 participantsCity of Hope Medical Center

View Study Details

NCT04634552Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3)....

Duarte, CAPHASE2510 participantsJanssen Research & Development, LLC

View Study Details

NCT07555938Recruiting

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple my...

Duarte, CAPHASE3380 participantsHoffmann-La Roche

View Study Details

NCT05201781Recruiting

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-te...

Duarte, CAPHASE4295 participantsJanssen Research & Development, LLC

View Study Details

NCT04973605Recruiting

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM)...

Duarte, CAPHASE1246 participantsBeiGene

View Study Details

NCT06106945Recruiting

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and prelimina...

Duarte, CAPHASE1226 participantsAstraZeneca

View Study Details

NCT06121843Recruiting

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants w...

Duarte, CAPHASE1187 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT06153251Recruiting

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM)....

Duarte, CAPHASE1187 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT05652335Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and to...

Duarte, CAPHASE1180 participantsJanssen Research & Development, LLC

View Study Details

NCT07266441Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells c...

Duarte, CAPHASE2157 participantsJanssen Research & Development, LLC

View Study Details

NCT07409246Recruiting

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety, tolerability, and how ABBV-438 ...

Duarte, CAPHASE1127 participantsAbbVie

View Study Details

NCT07086976Recruiting

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

This is a parallel-group, Phase 3, double-blind, 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb response (DHR) compared with placebo in approx...

Duarte, CAPHASE390 participantsSanofi

View Study Details

NCT07075185Recruiting

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma....

Duarte, CAPHASE170 participantsKelonia Therapeutics, Inc.

View Study Details

NCT07073547Recruiting

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM)....

Duarte, CAPHASE140 participantsAstraZeneca

View Study Details

NCT04508790Recruiting

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

This phase II trial studies how well leflunomide, pomalidomide, and dexamethasone work for the treatment of multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory)...

Duarte, CAPHASE229 participantsCity of Hope Medical Center

View Study Details

NCT06572605Recruiting

External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease

This phase I/II trial tests the safety and effectiveness of extramedullary disease (EMD)-directed external beam radiation therapy (EBRT) in combination with talquetamab for the treatment of multiple m...

Duarte, CAPHASE120 participantsCity of Hope Medical Center

View Study Details

NCT05363111Recruiting

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

This phase I trial tests the safety, side effects, and best dose of actinium Ac 225-DOTA-daratumumab (225Ac-DOTA-daratumumab) in combination with daratumumab and indium In 111-DOTA-daratumumab (111In-...

Duarte, CAPHASE115 participantsCity of Hope Medical Center

View Study Details

NCT06048250Recruiting

Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma

This phase I trial studies the safety, side effects, best dose and effectiveness of mezigdomide (CC-92480) when given after idecabtagene vicleucel (Abecma chimeric antigen receptor \[CAR\] T-cell ther...

Duarte, CAPHASE115 participantsCity of Hope Medical Center

View Study Details

About Multiple Myeloma Clinical Trials in Duarte

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 19 multiple myeloma clinical trials recruiting participants in Duarte, CA. These studies are seeking a combined 5,064 participants. Research is being sponsored by Janssen Research & Development, LLC, City of Hope Medical Center, Hoffmann-La Roche and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Duarte — FAQ

Are there multiple myeloma clinical trials in Duarte?

Yes, there are 19 multiple myeloma clinical trials currently recruiting in Duarte, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Duarte?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Duarte research site will contact you about next steps.

Are clinical trials in Duarte free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Duarte studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 19 active trials in Duarte are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated July 19, 2026 from ClinicalTrials.gov